In this study, we report the efficacy, safety, and immunogenicity of BIMERVAX® in cynomolgus macaque model of SARS-CoV-2 we developed with Cynbiose. Prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, BIMERVAX® vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respiratory tract after an experimental infection.

Our synergistical public-private partnership with Cynbiose and the exceptional financial support of the Région Auvergne-Rhône-Alpes at the time the SARS-CoV-2 pandemic was at its peak, have enabled us to develop and characterize a first NHP model of SARS-CoV-2 infection from the first half of 2020 (#Covibiose project). We also thank you Lyonbiopole for its confidence in our innovation and our ability to create values and contribute to the fight against emerging and reemerging infectious diseases.

It is a real satisfaction to have contributed actively to accelerate the transfer to clinical trial of the HIPRA’s Covid-19 vaccine, which was approved by the European Medecines Agency in April 2023. This gives meaning and significance to our long-standing commitment and our research work in Human Health.

Publication and press release :

For more informations :